G-CSF Biosimilars Approved By EU Could Impact Amgen Sales
This article was originally published in The Pink Sheet Daily
Executive Summary
Competitors to Amgen’s Neupogen and Neulasta soon could be joined by CT Arzneimittel’s proposed filgrastim product.